Analysis and validation of prognostic factors for CML

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Hasford, J ^a,b   Ansari, H ^a   Pfirrmann, M ^b   Hehlmann, R ^c  

^a Biometrisches Zentrum F T   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myeloid leukemia; Cox stepwise regression model; Kantarjian's staging system; Prognostic factors; Risk adjusted treatment; Sokal index

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN;

CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; EOSINOPHIL; ERYTHROBLAST; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, ABL; GERMANY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0029897468     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
2. Kantarjian HM, Keating M, Smith TL et al. Proposal for a simple synthesis prognostic staging system in chronic myelogeneous leukemia. Am J Med 1990; 88: 1-8.
3. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-αnl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
5. Hehlmann R, Heimpel H, Griesshammer M et al. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. Leukemia 1992; 6: 110S-114S.
6. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
7. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of Interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
8. Tura S, Baccarani M, Corbelli G et al. Staging of chronic myeloid leukaemia. Br J Haematol 1981; 47: 105-119.
9. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 60: 1298-1304.
10. Kantarjian HM, Smith TL, McCredie KB et al. Chronic myelogeneous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.
11. Hehlmann R, Heimpel H, Kolb HJ et al. The German CML Study, comparison of busulfan vs interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 1993; 11: 159-168.
12. Sokal JE, Baccarani M, Tura S et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985; 66: 1352-1357.
13. Thiele J, Kvasnicka HM, Zankovich R et al. Parameters of predictive value in chronic myeloid leukemia - The prognostic impact of histopathological variables in a multivariate regression analysis. Leuk Lymphoma 1991; 4: 63-74.
14. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogeneous leukemia. Effect on remission duration and survival: Cancer and Leukemia Group B Study 8593. Blood 1993; 82: 2975-2984.
15. Messerer D, Hasford J, Hoelzer D et al. Pitfalls in the evaluation of prognostic factors. Hematol Blood Transfus 1987; 30: 308-312.
16. Peduzzi PN, Detre KM, Chan YK et al. Validation of a risk function to predict mortality in a VA population with coronary artery disease. Controlled Clin Trials 1982; 3: 47-60.